S&P 500   3,324.93 (+1.65%)
DOW   26,762.03 (+0.91%)
QQQ   278.58 (+2.55%)
AAPL   116.37 (+4.65%)
MSFT   206.37 (+1.82%)
FB   282.79 (+5.65%)
GOOGL   1,581.39 (+4.67%)
AMZN   3,228.27 (+2.07%)
TSLA   414.24 (+2.02%)
NVDA   525.53 (+4.05%)
BABA   314.48 (+2.12%)
CGC   18.90 (+3.05%)
GE   7.40 (-0.27%)
MU   50.77 (+1.54%)
AMD   78.76 (+3.09%)
T   26.92 (+1.58%)
F   7.96 (+3.38%)
ACB   4.05 (+5.74%)
GILD   58.75 (+0.05%)
NFLX   495.59 (+1.92%)
NIO   31.78 (+15.52%)
BA   148.71 (+0.38%)
DIS   121.91 (+2.90%)
S&P 500   3,324.93 (+1.65%)
DOW   26,762.03 (+0.91%)
QQQ   278.58 (+2.55%)
AAPL   116.37 (+4.65%)
MSFT   206.37 (+1.82%)
FB   282.79 (+5.65%)
GOOGL   1,581.39 (+4.67%)
AMZN   3,228.27 (+2.07%)
TSLA   414.24 (+2.02%)
NVDA   525.53 (+4.05%)
BABA   314.48 (+2.12%)
CGC   18.90 (+3.05%)
GE   7.40 (-0.27%)
MU   50.77 (+1.54%)
AMD   78.76 (+3.09%)
T   26.92 (+1.58%)
F   7.96 (+3.38%)
ACB   4.05 (+5.74%)
GILD   58.75 (+0.05%)
NFLX   495.59 (+1.92%)
NIO   31.78 (+15.52%)
BA   148.71 (+0.38%)
DIS   121.91 (+2.90%)
S&P 500   3,324.93 (+1.65%)
DOW   26,762.03 (+0.91%)
QQQ   278.58 (+2.55%)
AAPL   116.37 (+4.65%)
MSFT   206.37 (+1.82%)
FB   282.79 (+5.65%)
GOOGL   1,581.39 (+4.67%)
AMZN   3,228.27 (+2.07%)
TSLA   414.24 (+2.02%)
NVDA   525.53 (+4.05%)
BABA   314.48 (+2.12%)
CGC   18.90 (+3.05%)
GE   7.40 (-0.27%)
MU   50.77 (+1.54%)
AMD   78.76 (+3.09%)
T   26.92 (+1.58%)
F   7.96 (+3.38%)
ACB   4.05 (+5.74%)
GILD   58.75 (+0.05%)
NFLX   495.59 (+1.92%)
NIO   31.78 (+15.52%)
BA   148.71 (+0.38%)
DIS   121.91 (+2.90%)
S&P 500   3,324.93 (+1.65%)
DOW   26,762.03 (+0.91%)
QQQ   278.58 (+2.55%)
AAPL   116.37 (+4.65%)
MSFT   206.37 (+1.82%)
FB   282.79 (+5.65%)
GOOGL   1,581.39 (+4.67%)
AMZN   3,228.27 (+2.07%)
TSLA   414.24 (+2.02%)
NVDA   525.53 (+4.05%)
BABA   314.48 (+2.12%)
CGC   18.90 (+3.05%)
GE   7.40 (-0.27%)
MU   50.77 (+1.54%)
AMD   78.76 (+3.09%)
T   26.92 (+1.58%)
F   7.96 (+3.38%)
ACB   4.05 (+5.74%)
GILD   58.75 (+0.05%)
NFLX   495.59 (+1.92%)
NIO   31.78 (+15.52%)
BA   148.71 (+0.38%)
DIS   121.91 (+2.90%)
Log in
NASDAQ:OPRX

OptimizeRx Stock Forecast, Price & News

$20.77
+0.74 (+3.69 %)
(As of 10/29/2020 02:52 PM ET)
Add
Compare
Today's Range
$19.80
Now: $20.77
$21.07
50-Day Range
$18.12
MA: $20.39
$21.93
52-Week Range
$6.50
Now: $20.77
$22.55
Volume4,666 shs
Average Volume130,383 shs
Market Capitalization$307.75 million
P/E RatioN/A
Dividend YieldN/A
Beta0.56
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems to search, print, or electronically dispense directly to patients, as well as for a network of pharmacies; and Brand and Clinical Messaging that includes various brand awareness and clinical messaging services consisting of brand awareness messages, reminder ads, clinical messages, and unbranded messages targeted by specialty, diagnostic code, and other criteria. The company's products and applications also comprise brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing new eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. It also operates Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence, care coordination, and patient engagement; and HIPAA-compliant, an automated and mobile messaging platform that allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. OptimizeRx Corporation is based in Rochester, Michigan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars

Industry, Sector and Symbol

Industry Business services, not elsewhere classified
Sub-IndustryN/A
Current SymbolNASDAQ:OPRX
CUSIPN/A
CIKN/A
Phone248-651-6568
Employees37

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.60 million
Book Value$3.17 per share

Profitability

Net Income$-3,140,000.00

Miscellaneous

Market Cap$307.75 million
Next Earnings Date11/9/2020 (Confirmed)
OptionableNot Optionable
$20.77
+0.74 (+3.69 %)
(As of 10/29/2020 02:52 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OptimizeRx (NASDAQ:OPRX) Frequently Asked Questions

How has OptimizeRx's stock price been impacted by Coronavirus?

OptimizeRx's stock was trading at $7.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OPRX shares have increased by 177.5% and is now trading at $20.84.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of OptimizeRx?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for OptimizeRx
.

When is OptimizeRx's next earnings date?

OptimizeRx is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for OptimizeRx
.

How can I listen to OptimizeRx's earnings call?

OptimizeRx will be holding an earnings conference call on Monday, November 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) issued its quarterly earnings data on Wednesday, August, 5th. The company reported $0.02 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.03) by $0.05. The business earned $8.78 million during the quarter, compared to analyst estimates of $8.02 million. OptimizeRx had a negative net margin of 23.79% and a negative return on equity of 14.44%.
View OptimizeRx's earnings history
.

What guidance has OptimizeRx issued on next quarter's earnings?

OptimizeRx issued an update on its third quarter 2020 Pre-Market earnings guidance on Tuesday, October, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $10 million, compared to the consensus revenue estimate of $9.1 million.

What price target have analysts set for OPRX?

4 analysts have issued 12-month target prices for OptimizeRx's stock. Their forecasts range from $20.00 to $40.00. On average, they anticipate OptimizeRx's stock price to reach $29.33 in the next year. This suggests a possible upside of 40.8% from the stock's current price.
View analysts' price targets for OptimizeRx
.

Who are some of OptimizeRx's key competitors?

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), Stag Industrial (STAG), Etsy (ETSY), Marvell Technology Group (MRVL), The Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

Who are OptimizeRx's key executives?

OptimizeRx's management team includes the following people:
  • Mr. William J. Febbo, CEO & Director (Age 50)
  • Ms. Miriam J. Paramore, Pres (Age 56)
  • Mr. Douglas P. Baker, Chief Financial Officer (Age 62)
  • Mr. Terence J. Hamilton, Sr. VP of Sales (Age 54)
  • Mr. James Brooks, Consultant (Age 50)

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by a variety of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (1.14%), Handelsinvest Investeringsforvaltning (0.54%) and Harel Insurance Investments & Financial Services Ltd. (0.15%). Company insiders that own OptimizeRx stock include Awm Investment Company, Inc, Douglas P Baker, Ellen O'connor Vos, Gregory D Wasson, Gus D Halas, Miriam J Paramore and William J Febbo.
View institutional ownership trends for OptimizeRx
.

Which institutional investors are buying OptimizeRx stock?

OPRX stock was bought by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Handelsinvest Investeringsforvaltning, and Harel Insurance Investments & Financial Services Ltd.. Company insiders that have bought OptimizeRx stock in the last two years include Ellen O'connor Vos, Gregory D Wasson, Gus D Halas, Miriam J Paramore, and William J Febbo.
View insider buying and selling activity for OptimizeRx
.

How do I buy shares of OptimizeRx?

Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $20.84.

How big of a company is OptimizeRx?

OptimizeRx has a market capitalization of $308.79 million and generates $24.60 million in revenue each year. The company earns $-3,140,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. OptimizeRx employs 37 workers across the globe.

What is OptimizeRx's official website?

The official website for OptimizeRx is www.optimizerx.com.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company can be reached via phone at 248-651-6568 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.